|
US6150354A
(en)
*
|
1987-01-15 |
2000-11-21 |
Bonnie Davis |
Compounds for the treatment of Alzheimer's disease
|
|
ATE411026T1
(de)
*
|
1987-05-04 |
2008-10-15 |
Bonnie Davis |
Mittel zur behandlung der alzheimer-krankheit
|
|
IT1222395B
(it)
*
|
1987-07-30 |
1990-09-05 |
Pierrel Spa |
Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
|
|
US4897388A
(en)
*
|
1988-12-20 |
1990-01-30 |
Geriatric Research Institute, Inc. |
Method of treating Alzheimer's disease
|
|
DE4010079A1
(de)
*
|
1990-03-29 |
1991-10-02 |
Lohmann Therapie Syst Lts |
Pharmazeutische formulierung zur behandlung des alkoholismus
|
|
US5519017A
(en)
*
|
1990-03-29 |
1996-05-21 |
Lts Lohmann Therapie-Systeme Gmbh + Co. Kg |
Pharmaceutic formulation for the treatment of alcoholism
|
|
EP0584185B1
(en)
*
|
1991-05-14 |
1999-08-11 |
Ernir Snorrason |
Treatment of fatigue syndrome with cholinesterase inhibitors
|
|
US5336675A
(en)
*
|
1991-05-14 |
1994-08-09 |
Ernir Snorrason |
Method of treating mania in humans
|
|
US5177070A
(en)
*
|
1991-11-15 |
1993-01-05 |
Ciba-Geigy Corporation |
Method of treating physiologic male erectile impotence
|
|
DE4301782C1
(de)
*
|
1993-01-23 |
1994-08-25 |
Lohmann Therapie Syst Lts |
Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
|
|
DE4301783C1
(de)
*
|
1993-01-23 |
1994-02-03 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
|
|
US6323196B1
(en)
*
|
1993-10-15 |
2001-11-27 |
Aventis Pharmaceuticals Inc. |
Galanthamine derivatives as acetylcholinesterase inhibitors
|
|
US6316439B1
(en)
|
1993-10-15 |
2001-11-13 |
Aventis Pharamaceuticals Inc. |
Galanthamine derivatives as acetylcholinesterase inhibitors
|
|
US6323195B1
(en)
*
|
1993-10-15 |
2001-11-27 |
Aventis Pharmaceuticals Inc. |
Galanthamine derivatives as acetylcholinesterase inhibitors
|
|
AU695352B2
(en)
*
|
1994-10-21 |
1998-08-13 |
Sanochemia Pharmazeutika Ag |
Process for producing derivatives of 4a,5,9,10,11,12,-hexahydro-6h-benzofuro{3a,3,2-ef}{2} benzazepine
|
|
US6407229B1
(en)
|
1994-10-21 |
2002-06-18 |
Sanochemia Pharmazeutika Ag |
Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
|
|
DE19509663A1
(de)
|
1995-03-17 |
1996-09-19 |
Lohmann Therapie Syst Lts |
Verfahren zur Isolierung von Galanthamin
|
|
GB9514821D0
(en)
*
|
1995-07-19 |
1995-09-20 |
Sod Conseils Rech Applic |
Galanthamine derivatives
|
|
AT402691B
(de)
*
|
1996-01-26 |
1997-07-25 |
Sanochemia Ltd |
Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
|
|
AT403803B
(de)
*
|
1996-04-19 |
1998-05-25 |
Sanochemia Ltd |
Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
|
|
TW506836B
(en)
*
|
1996-06-14 |
2002-10-21 |
Janssen Pharmaceutica Nv |
Fast-dissolving galanthamine hydrobromide tablet
|
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
|
JP5558648B2
(ja)
*
|
1998-11-23 |
2014-07-23 |
デイビス、ボニー |
アセチルコリンエステラーゼ阻害剤のための投与製剤
|
|
AU2004242546B2
(en)
*
|
1998-11-23 |
2008-05-15 |
Bonnie Davis |
Dosage formulations for acetylcholinesterase inhibitors
|
|
PL349501A1
(en)
*
|
1998-12-24 |
2002-07-29 |
Janssen Pharmaceutica Nv |
Controlled release galantamine composition
|
|
US20050063998A1
(en)
*
|
1999-10-26 |
2005-03-24 |
Francois Marc Karel Jozef |
Oral solution containing galantamine and a sweetening agent
|
|
US6426097B2
(en)
|
2000-01-28 |
2002-07-30 |
Herbaceuticals Inc. |
Herbal supplement for cognitive related impairment due to estrogen loss
|
|
PT1261345E
(pt)
*
|
2000-01-28 |
2005-10-31 |
Tricia Grose |
Suplemento herbaceo para enfraquecimento relacionado com o sistema cognitivo devido a perda de estrogenio
|
|
CA2368966A1
(en)
|
2000-03-31 |
2001-10-11 |
Sanochemia Pharmazeutika Aktiengesellschaft |
New derivatives and analogues of galanthamine
|
|
CA2310926C
(en)
|
2000-04-03 |
2002-10-15 |
Janssen Pharmaceutica N.V. |
A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
|
|
CA2310990A1
(en)
|
2000-04-03 |
2000-10-09 |
Michael Pontecorvo |
A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
|
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
|
JP4721386B2
(ja)
*
|
2001-07-10 |
2011-07-13 |
第一三共株式会社 |
新規ガランタミン類縁体
|
|
US20030162770A1
(en)
*
|
2002-02-22 |
2003-08-28 |
Davis Bonnie M. |
Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
|
|
NZ537090A
(en)
|
2002-06-14 |
2006-02-24 |
Toyama Chemical Co Ltd |
Medicinal compositions improving brain function and method for improving brain function
|
|
US20040067934A1
(en)
*
|
2002-10-03 |
2004-04-08 |
Parys Wim Louis Julien |
Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
|
|
US20040087658A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Hans-Joerg Moebius |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
|
US20040097484A1
(en)
*
|
2002-11-14 |
2004-05-20 |
Marc Cantillion |
Once a day galantamine pharmaceutical compositions and methods of use
|
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
|
WO2004108085A2
(en)
*
|
2003-05-30 |
2004-12-16 |
Microbia, Inc. |
Methods for the protection of memory and cognition
|
|
US20050048543A1
(en)
*
|
2003-07-11 |
2005-03-03 |
Jeroen Aerssens |
CHRNA2 genetic markers associated with galantamine response
|
|
EP1651195A4
(en)
*
|
2003-07-11 |
2007-10-03 |
Myriad Genetics Inc |
PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
|
|
CA2532347C
(en)
*
|
2003-07-25 |
2012-03-27 |
F. Hoffmann-La Roche Ag |
Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
|
|
US20050260613A1
(en)
*
|
2003-10-28 |
2005-11-24 |
Genaissance Pharmaceuticals |
LRPAP1 genetic markers associated with galantamine
|
|
BG65658B1
(bg)
*
|
2003-11-13 |
2009-05-29 |
"Софарма" Ад |
Комбиниран лекарствен продукт на основата на галантамин
|
|
US20050143350A1
(en)
*
|
2003-11-19 |
2005-06-30 |
Seed John C. |
Combination drug therapy to treat obesity
|
|
US7250258B2
(en)
*
|
2003-12-15 |
2007-07-31 |
Pgxhealth Llc |
CDK5 genetic markers associated with galantamine response
|
|
CA2551946A1
(en)
*
|
2003-12-31 |
2005-07-21 |
Actavis Group Hf |
Immediate, controlled and sustained release formulations of galantamine
|
|
US20050142193A1
(en)
*
|
2003-12-31 |
2005-06-30 |
Lijuan Tang |
Galantamine formulations
|
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
|
CN1946906A
(zh)
*
|
2004-04-29 |
2007-04-11 |
吉斯通护岸系统股份有限公司 |
用于墙、护墙和类似物的饰面
|
|
JP2007537294A
(ja)
*
|
2004-05-14 |
2007-12-20 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
Ｇａｂａｂレセプターアンタゴニストとアセチルコリンエステラーゼインヒビターとの同時投与により認識機能を改善するための方法
|
|
EP1779867A4
(en)
*
|
2004-07-01 |
2009-12-02 |
Eisai R&D Man Co Ltd |
MEANS FOR PROMOTING NERVE REVENERATION
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
AU2005308575A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Warner-Lambert Company Llc |
7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
|
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
|
EP1827468B1
(en)
*
|
2004-12-23 |
2012-08-22 |
Curaxis Pharmaceutical Corporation |
Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
|
|
WO2006121560A2
(en)
|
2005-04-06 |
2006-11-16 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for treatment of cns disorders
|
|
US20080188510A1
(en)
*
|
2005-05-23 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
Novel methods using zonisamide
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
KR20080039876A
(ko)
*
|
2005-07-22 |
2008-05-07 |
미리어드 제네틱스, 인크. |
높은 약물 충진 제형 및 투여형
|
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
|
BRPI0718437A2
(pt)
|
2006-10-27 |
2013-11-19 |
Medivation Neurology Inc |
Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
|
|
US8404701B2
(en)
*
|
2008-03-27 |
2013-03-26 |
Chase Pharmaceuticals Corporation |
Use and composition for treating dementia
|
|
US20110201597A1
(en)
|
2008-03-27 |
2011-08-18 |
Chase Thomas N |
Method and composition for treating alzheimer-type dementia
|
|
ES2746480T3
(es)
|
2009-09-18 |
2020-03-06 |
Chase Pharmaceuticals Corp |
Combinación para tratar demencia de tipo Alzheimer
|
|
BR112012012766A2
(pt)
|
2009-11-26 |
2016-09-06 |
Usv Ltd |
composicões farmacêuticas de galantamina de liberação controlada
|
|
CA2789014C
(en)
|
2010-02-09 |
2019-01-15 |
Michela Gallagher |
Methods and compositions for improving cognitive function
|
|
WO2011151359A1
(en)
|
2010-06-02 |
2011-12-08 |
Noscira, S.A. |
Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
|
|
FR2962335B1
(fr)
|
2010-07-12 |
2013-01-18 |
Cll Pharma |
Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
|
|
AU2013312749B2
(en)
|
2012-09-05 |
2018-01-18 |
Chase Pharmaceuticals Corporation |
Anticholinergic neuroprotective composition and methods
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
BG66818B1
(bg)
|
2013-03-07 |
2019-01-31 |
Berbee Beheer B. V. |
Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
|
|
US11160785B2
(en)
|
2013-03-15 |
2021-11-02 |
Agenebio Inc. |
Methods and compositions for improving cognitive function
|
|
EP2968237A4
(en)
|
2013-03-15 |
2016-08-31 |
Univ Johns Hopkins |
METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
|
|
CA2921308A1
(en)
|
2013-08-16 |
2015-02-19 |
Universiteit Maastricht |
Treatment of cognitive impairment with pde4 inhibitor
|
|
EA034167B8
(ru)
|
2015-05-22 |
2021-04-27 |
Эйджинбайо, Инк. |
Фармацевтические композиции леветирацетама пролонгированного высвобождения
|